Imprimis Pharmaceuticals, Inc. IMMY was a big mover last session, as its shares rose roughly 11% on the day. The upside was driven by the news that Express Scripts Holding Company ESRX has entered into a partnership with Imprimis Pharmaceuticals to provide a low-cost version of Daraprim, which is used in the treatment of toxoplasmosis. This also led to far more shares changing hands than in a normal session. Yesterday’s rally breaks the trend for the company since Nov 3, as the stock is now trading above the volatile price range of $5.11 to $7.36.
Over the last 30 days, the company witnessed one negative estimate revision and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.
Imprimis Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Is IMMY going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment